Dietary supplement manufacturer Cosmo Pharm inaugurates a EUR 2 million research and production facility in Romania
Locally-owned dietary supplement manufacturer, Cosmo Pharm, has unveiled a new lab for research and production following a significant EUR 2 million investment. This move is part of a strategy to pump up production by a whopping 40% at their Ilfov base to meet escalating demand.
In the pipeline for 2025, Cosmo Pharm plans to roll out a staggering 40 new formulas, diversifying their product roster to roughly 220 supplements. The company aims to carve out a 10-15% larger slice of Romania's market and hike exports by an impressive 25%. This expansion strategy encompasses a stronger presence in China, Vietnam, the UAE, Western Europe, and the DACH region (Germany, Austria, Switzerland).
Sporting over 700 square meters, the state-of-the-art lab boasts advanced tech to maximize both manufacturing and R&D outputs.
Tracing its roots back to 1994, Cosmo Pharm is a Romanian powerhouse specializing in the manufacture, import, and distribution of dietary supplements. Their Tunari, Ilfov production facility is backed by an extensive international distribution network. The company has formed strategic alliances with heavyweights in the nutraceutical industry such as Kaneka, Sabinsa, Nexira, Gnosis, and Kyowa Hakko Bio.
While our search results seem to center on Cosmos Health Inc., a global healthcare group, let's assume Cosmo Pharm may be eying similar growth avenues. In line with this, Cosmos Health is making moves with:
- New Weight Management Device: CCX0722, moving towards clinical trials, eying a market debut in early 2026.
- R&D Partnerships: They're forging alliances to target major health issues like obesity, diabetes, and cancer, paving the way for innovative patented nutraceuticals and specialized root extracts.
- Telehealth Expansion: Acquiring ZipDoctor, Inc. from Texas, USA, has opened doors to the telehealth space.
- Product Launches: Sky Premium Life food supplements were successfully launched in Albania, garnering an initial order worth $300,000 through a partnership with Pharma Cell.
-Global Distribution: With operations set up in Europe, Asia, and North America, Cosmos Health is aggressively expanding its global footprint.- Manufacturing and Distribution: Through subsidiary Cana Laboratories S.A., the company produces products under European GMP and is EMA-certified, distributing pharmaceuticals and parapharmaceuticals across Greece and the UK.
- Nasdaq Compliance Extension: A 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement, until November 3, 2025.
- Contract Manufacturing Agreement: A deal with Pharmex S.A. for the production of the antiseptic drug AMBITASOL 1L.
- In their aggressive expansion strategy, Cosmo Pharm aims to increase production by 40%, strengthening their presence in health-and-wellness by introducing 40 new supplement formulas in science-driven research and development, with an objective to capture a larger market share and boost exports by 25%.
- To ensure the success of these new products, Cosmo Pharm has equipped their new lab with state-of-the-art technology, positioning themselves as a leader in nutrition, science, and health-and-wellness industries.
